Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24

• Verfasst von: Christensen, Olaf [VerfasserIn]
• Verfasst von: Lupu, Alaviana [VerfasserIn]
• Verfasst von: Schmidt, Stefanie [VerfasserIn]
• Verfasst von: Condomines, Maud [VerfasserIn]
• Verfasst von: Belle, Sebastian [VerfasserIn]
• Verfasst von: Maier, Ariane [VerfasserIn]
• Verfasst von: Hose, Dirk [VerfasserIn]
• Verfasst von: Neuber, Brigitte [VerfasserIn]
• Verfasst von: Moos, Marion [VerfasserIn]
• Verfasst von: Kleist, Christian [VerfasserIn]
• Verfasst von: Terness, Peter [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Klein, Bernard [VerfasserIn]
• Verfasst von: Hundemer, Michael [VerfasserIn]
• Titel: Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24
• Verf.angabe: Olaf Christensen, Alaviana Lupu, Stefanie Schmidt, Maud Condomines, Sebastian Belle, Ariane Maier, Dirk Hose, Brigitte Neuber, Marion Moos, Christian Kleist, Peter Terness, Anthony D. Ho, Hartmut Goldschmidt, Bernard Klein, and Michael Hundemer
• E-Jahr: 2009
• Jahr: [July-August 2009]
• Umfang: 9 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 14.01.2022
• Titel Quelle: Enthalten in: Journal of immunotherapy
• Ort Quelle: Philadelphia, Pa. : Lippincott Williams & Wilkins, 1991
• Jahr Quelle: 2009
• Band/Heft Quelle: 32(2009), 6, Seite 613-621
• ISSN Quelle: 1537-4513
• DOI: doi:10.1097/CJI.0b013e3181a95198
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1786039001

Abstract

The Melan-Aaa26-35 (EAAGIGILTV) peptide is a human leukocyte antigen (HLA)-A2-restricted T-cell epitope within the Melan-A/MART-1 tumor antigen expressed on malignant melanoma cells. Melan-A and Melan-A analog (ELAGIGILTV, Melan-Aaa26-35*A27L) specific T-cells can be expanded reliably for immunotherapeutic approaches in vitro. We studied the ability of Melan-A analog (ELAGIGILTV, Melan-Aaa26-35*A27L) specific T-cells to recognize the HM1.24aa22−30 (LLLGIGILV) peptide within the HM1.24 antigen presented by normal and malignant plasma cells. Peripheral blood mononuclear cells from HLA-A2+ healthy donors and HLA-A2+ multiple myeloma (MM) patients were stimulated with Melan-A analog peptide-loaded autologous dendritic cells, and expanded in vitro. T-cell activation was assessed by interferon-γ specific enzyme-linked immunosorbent spot and cytotoxicity by 51Chromium-release-assays. The frequency of Melan-A analog specific CD8+ T-cells was detected by using tetramers. Melan-A analog specific T-cells from HLA-A2+ healthy donors and HLA-A2+ MM patients showed a interferon-γ secretion mediated by HM1.24aa22−30 peptide-pulsed T2 cells and lysed the HLA-A2+ HM1.24+ U266 and XG-1 human myeloma derived cell-lines as well as the B-lymphoblastoid cell-line IM-9. Melan-A analog specific T-cells from MM patients specifically lysed autologous MM cells. The current data demonstrate that Melan-A analog specific T-cells crossreact with HM1.24aa22−30. They might be a tool for the future use in immunotherapy against MM.